Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Gilead Sciences, Inc.

Gilead Sciences, Inc. (GILD) Stock Overview

Explore Gilead Sciences, Inc.’s financial performance, market position, analyst ratings, and future outlook.

GILD●NASDAQ
HealthcareDrug Manufacturers - General
$151.17
$4.32(2.94%)
U.S. Market opens in 34h 6m

Gilead Sciences, Inc. (GILD)

Meyka AI Score

Z

Key Financials

Market Cap182.4B
P/E Ratio-57.96
EPS (TTM)$-0.39
ROE-0.16%
Fundamental Analysis

AI Price Forecasts

1 Month$153.03
3 Months$149.43
1 Year Target$160.42

GILD Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Gilead Sciences, Inc. (NASDAQ: GILD) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Gilead Sciences, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of GILD on the NASDAQ shows an RSI of 58.98, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $160.42 for the NASDAQ listing.

Key metrics behind Gilead Sciences, Inc.'s NASDAQ-traded stock include a P/E ratio of -57.96 and a market capitalization of 182.4B. Combined with our AI analysis, these give both institutional and retail investors a clear view of GILD on the NASDAQ.

Price Performance (NASDAQ: GILD)

1-Day Change
2.77%
5-Day Change
2.38%
1-Month Change
3.79%
3-Month Change
12.11%
6-Month Change
6.39%
Year-to-Date (YTD) Change
23.16%
1-Year Change
29.49%
3-Year Change
101.40%
5-Year Change
122.05%
All-Time (Max) Change
23788.69%

Contact Information

https://www.gilead.com
650 574 3000
333 Lakeside Drive, Foster City, CA, 94404

Company Facts

170,000 Employees
IPO DateJan 22, 1992
CountryUS
Actively Trading

Frequently Asked Questions